Novel selective agents for the degradation of AR/AR-V7 to treat advanced prostate cancer.
Yang Y, Lv G, Xiu R, Yang H, Wang W, Yu P, Zhang J, Ye L, Wang H, Tian J.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2024.116400 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för apalutamide. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
12 träffarDesign and Synthesis of Dual-Target Inhibitors Targeting Androgen Receptors and Glucocorticoid Receptors to Overcome Antiandrogen Resistance in Castration-Resistant Prostate Cancer.
Li C, Han X, Yan Q, Ji Y, Zhang R, Yuan D, Yang F, Wang J, Wu M, Zhou J.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.3c01668Synthesis and clinical application of small-molecule drugs approved to treat prostatic cancer.
Zhang JY, Zhao LJ, Wang YT.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2023.115925Elevated labile iron in castration-resistant prostate cancer is targetable with ferrous iron-activatable antiandrogen therapy.
Gonciarz RL, Sakhamuri S, Hooshdaran N, Kumar G, Kim H, Evans MJ, Renslo AR.
Eur J Med Chem · research-article; journal article · DOI 10.1016/j.ejmech.2023.115110Therapeutic Strategies to Target the Androgen Receptor.
Xiang W, Wang S.
J Med Chem · research support, non-u.s. gov't; review; journal article; research support, n.i.h., extramural · DOI 10.1021/acs.jmedchem.2c00716Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.
Fu W, Zhang M, Liao J, Tang Q, Lei Y, Gong Z, Shan L, Duan M, Chai X, Pang J, Tang C, Wang X, Xu X, Li D, Sheng R, Hou T.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.1c01287Designing Out PXR Activity on Drug Discovery Projects: A Review of Structure-Based Methods, Empirical and Computational Approaches.
Hall A, Chanteux H, Ménochet K, Ledecq M, Schulze MED.
J Med Chem · review; journal article · DOI 10.1021/acs.jmedchem.0c02245Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.
He Y, Hwang DJ, Ponnusamy S, Thiyagarajan T, Mohler ML, Narayanan R, Miller DD.
J Med Chem · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1021/acs.jmedchem.0c00943New drug approvals for 2019: Synthesis and clinical applications.
Yuan S, Yu B, Liu HM.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2020.112667New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.
Hwang DJ, He Y, Ponnusamy S, Mohler ML, Thiyagarajan T, McEwan IJ, Narayanan R, Miller DD.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.8b00973Design, synthesis, and biological evaluation of deuterated apalutamide with improved pharmacokinetic profiles.
Pang X, Wang Y, Chen Y.
Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2017.04.071Design, synthesis and biological evaluation of novel 5-oxo-2-thioxoimidazolidine derivatives as potent androgen receptor antagonists.
Ivachtchenko AV, Ivanenkov YA, Mitkin OD, Vorobiev AA, Kuznetsova IV, Shevkun NA, Koryakova AG, Karapetian RN, Trifelenkov AS, Kravchenko DV, Veselov MS, Chufarova NV.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2015.05.039